Neurocrine Biosciences (NBIX) News Today $128.04 -1.37 (-1.05%) Closing price 03:51 PM EasternExtended Trading$127.38 -0.65 (-0.51%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Allspring Global Investments Holdings LLC Reduces Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)July 1 at 4:48 AM | marketbeat.comBessemer Group Inc. Lowers Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)July 1 at 3:56 AM | marketbeat.comNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor AntagonistJune 30 at 4:05 PM | prnewswire.comPeregrine Capital Management LLC Has $8.07 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 30 at 8:34 AM | marketbeat.com3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (NBIX)Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value...June 29, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Perpetual LtdJune 29, 2025 | marketbeat.comAsset Management One Co. Ltd. Has $7.43 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 28, 2025 | marketbeat.comJanney Montgomery Scott LLC Sells 4,677 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 28, 2025 | marketbeat.comNBIX - Neurocrine Biosciences Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMNBIX Neurocrine Biosciences, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease ChoreaJune 27, 2025 | prnewswire.comNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive DyskinesiaJune 20, 2025 | prnewswire.comSowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 20, 2025 | marketbeat.comPallas Capital Advisors LLC Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 14, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 14, 2025 | marketbeat.comNeurocrine Biosciences' SWOT analysis: biotech stock balances Ingrezza success with pipeline potentialJune 13, 2025 | investing.comStanley Laman Group Ltd. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by TobamJune 13, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys 367,315 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comHandelsbanken Fonder AB Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 13, 2025 | marketbeat.comDavis Investment Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 12, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 11, 2025 | marketbeat.comNeurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 10, 2025 | finanznachrichten.deAnalysts Issue Forecasts for NBIX FY2026 EarningsJune 10, 2025 | marketbeat.comCongress Asset Management Co. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 10, 2025 | marketbeat.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX stock newsJune 9, 2025 | gurufocus.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences names new Chief Information OfficerJune 9, 2025 | investing.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 9, 2025 | prnewswire.comGuggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor MeetingJune 6, 2025 | msn.comWealth Enhancement Advisory Services LLC Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 6, 2025 | marketbeat.comRhumbline Advisers Has $34.78 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 5, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 5, 2025 | marketbeat.comNxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568June 2, 2025 | globenewswire.comNeurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at Royal Bank of CanadaJune 2, 2025 | marketbeat.comNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive DyskinesiaJune 2, 2025 | prnewswire.comSummit Global Investments Sells 21,182 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 1, 2025 | marketbeat.comCentral Pacific Bank Trust Division Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 1, 2025 | marketbeat.comFirst Hawaiian Bank Has $724,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 1, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)June 1, 2025 | marketbeat.comKevin Charles Gorman Sells 9,613 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMay 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 31, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 9,613 SharesMay 30, 2025 | insidertrades.comLansforsakringar Fondforvaltning AB publ Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 30, 2025 | marketbeat.comSiemens Fonds Invest GmbH Buys Shares of 6,225 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 30, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Has $5.53 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 30, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Two Sigma Investments LPMay 30, 2025 | marketbeat.comDirector Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX)May 29, 2025 | gurufocus.comMackenzie Financial Corp Has $7.54 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)May 29, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼0.970.54▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼1116▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today Incyte News Today United Therapeutics News Today Exelixis News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Repligen News Today Madrigal Pharmaceuticals News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
